Simulations Plus (SLP) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 Jul, 2026Executive summary
First quarter fiscal 2026 revenue declined 3% year-over-year to $18.4 million, with services revenue up 16% and software revenue down 17%.
Net income increased to $0.7 million (diluted EPS $0.03), up from $0.2 million (diluted EPS $0.01) in the prior year, driven by improved gross margin and lower general and administrative expenses.
Gross margin improved to 59% from 54% year-over-year, reflecting lower software amortization and favorable service delivery mix.
Adjusted EBITDA was $3.5 million (19% margin), with adjusted diluted EPS of $0.13, both meeting expectations.
Strategic focus remains on building an integrated product ecosystem leveraging validated science, cloud performance, and AI, with positive client response to new AI features.
Financial highlights
Software revenue was $8.9 million (48% of total), down 17% year-over-year; services revenue was $9.5 million (52% of total), up 16%.
Gross margin: 59% overall; software gross margin 84%, services gross margin 36%.
Net income for Q1 FY26 was $0.7 million; adjusted EBITDA margin was 19%, down from 24% in the prior year.
Cash and short-term investments at quarter-end were $35.7 million, with no debt.
Operating expenses totaled $10.2 million, with increases in R&D and sales/marketing.
Outlook and guidance
Fiscal 2026 revenue guidance reaffirmed at $79–$82 million, representing 0–4% year-over-year growth.
Software revenue mix expected between 57%–62% for the year.
Adjusted EBITDA margin guidance: 26%–30%; adjusted diluted EPS: $1.03–$1.10.
Management expects existing cash, investments, and operating cash flow to be sufficient for operating and capital needs for the next 12 months and beyond.
Q2 revenue expected to be $21–$22 million.
Latest events from Simulations Plus
- Q3 FY26 revenue up 7%, services up 20%, net income $3.6M, merger at $18.50/share pending.SLP
Q3 20269 Jul 2026 - Shareholders to vote on $18.50/share cash merger, with board unanimous support and 26% premium.SLP
Proxy filing9 Jul 2026 - FY24 revenue up 18% to $70M; FY25 guidance strong with Pro-ficiency driving growth.SLP
Q4 20249 Jul 2026 - FY25 guidance targets $90M-$93M revenue, 31%-33% EBITDA margin, and expanded market reach.SLP
Stephens 26th Annual Investment Conference | NASH20248 Jul 2026 - $100M acquisition doubles market, expands platform, and boosts 2025 EPS outlook.SLP
M&A Announcement8 Jul 2026 - OBESITYsym predicts weight loss and nausea for obesity drugs, validated across diverse populations.SLP
Status update23 Jun 2026 - Q2 2026 revenue up 8% to $24.3M, with higher margins and strong outlook despite EPS guidance cut.SLP
Q2 202610 Apr 2026 - Integrated AI ecosystem and cross-selling drive future growth, with major upside in FY 2027.SLP
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - All proposals passed with strong support; no shareholder questions were raised.SLP
AGM 202612 Feb 2026